No Data
No Data
Sichuan Kelun Pharmaceutical (002422.SZ): In 2024, the interim options distribution will be 2.6 yuan per 10 shares with a record date of October 22nd.
On October 16, Kelun Hui announced that Sichuan Kelun Pharmaceutical (002422.SZ) disclosed that the company's 2024 interim equity distribution plan is as follows: The company's total share capital is 1,601,592,173 shares, deducting 10,716,165 shares of the company's stocks in the repurchase special securities account. Based on a base of 1,590,876,008 shares, the company will distribute a cash dividend of 2.600000 yuan (tax inclusive) for every 10 shares to all shareholders (excluding the repurchase special securities account). The equity distribution registration date for this time is October 22, 2024, and the ex-dividend date is October 23, 2024.
Sichuan Kelun Pharmaceutical's (SZSE:002422) 24% CAGR Outpaced the Company's Earnings Growth Over the Same Three-year Period
We Think Sichuan Kelun Pharmaceutical (SZSE:002422) Can Manage Its Debt With Ease
Sichuan Kelun Pharmaceutical Gets Drug Registration Approval for Dydrogesterone Tablets
Sichuan Kelun Pharmaceutical (002422.SZ) has obtained pharmaceutical registration approval for its Diqutunone tablets.
Sichuan Kelun Pharmaceutical (002422.SZ) announced on September 18th that the company's chemical drug "Diqukun Pill" has recently obtained the drug registration approval from the National Medical Products Administration. It is reported that Diqukun Pill, developed by Abbott Laboratories, has been approved for sale in more than 100 countries, and is used to treat related diseases caused by endogenous progesterone deficiency, such as dysmenorrhea, endometriosis, threatened miscarriage or habitual miscarriage caused by progesterone deficiency, and luteal support in assisted reproduction technology. Diqukun is a synthetic progesterone that has the closest structure and function to natural progesterone. Compared with natural progesterone progesterone, its
Sichuan Kelun Pharmaceutical to Present Results of Cancer Drug Studies at Barcelona Oncology Meet
No Data
No Data